Structure-based peptide inhibitors of alpha-synuclein aggregation

US10815271B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• David S. Eisenberg · Los Angeles, US
• Smriti Sangwan · Los Angeles, US
• Lin Jiang · Los Angeles, US

Key dates

• Filing date: Jun 29, 2017
• Grant date: Oct 27, 2020
• Expiry date: Jun 29, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/2835
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to inhibitory peptides which bind to α-synuclein molecules and inhibit α-synuclein amyloidogenic aggregation, α-synuclein cytotoxicity, and spread of α-synuclein. Methods of making and using the inhibitory peptides (e.g. to treat subjects having conditions or diseases that are mediated by α-synuclein, such as Parkinson's disease, dementia with Lewy bodies, or MSA) are described.